

Airway neutrophilia in COPD is not associated with increased neutrophil survival

Paula Rytälä ^{1,2}, Maria Plataki ¹, Fabio Bucchieri ¹, Mohib Uddin ¹, Guangmin Nong ¹,
Vuokko L Kinnula ³, Ratko Djukanović ¹.

¹Division of Infection, Inflammation and Repair, University of Southampton, Southampton, United Kingdom.

²Division of Allergy, Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland

³Division of Respiratory Diseases, Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland

Correspondence and requests for reprints should be addressed to

Dr Paula Rytälä, M.D. PhD, Skin and Allergy Hospital, Helsinki University Central Hospital
Post Box 160, 00029 HUCH, Helsinki, Finland

Phone +358 9 471 86317

Fax +350 9 471 86500

E-mail paula.rytila@hus.fi

Short title: Neutrophil apoptosis in COPD

Key words: COPD, inflammation, neutrophils, apoptosis

Paula Rytälä is the recipient of a European Respiratory Society fellowship (LTRF2003-003).

Abstract

Neutrophilic airway inflammation is a prominent feature of chronic obstructive pulmonary disease (COPD) and correlates with disease severity. The mechanisms that determine the extent of neutrophilia could involve increased influx or prolonged survival of neutrophils. We wanted to assess whether neutrophil pro-survival mechanisms are increased in the airways of subjects with COPD due to the presence of anti-apoptotic factors in the bronchial lining fluid. Induced sputum samples were collected from 20 subjects with stable COPD, 14 healthy smokers and 14 healthy controls. Quantification of apoptotic neutrophils was based on typical morphological cell changes. The anti-apoptotic, pro-survival activity in the sputum was studied by culturing peripheral blood neutrophils with the fluid phase of induced sputum. Apoptosis was assessed both by morphology and flow cytometry using Annexin-7AAD staining. COPD-patients and healthy smokers had a significantly higher percentage of sputum neutrophils than healthy controls ($p < 0.0001$, $p = 0.01$). However, there were no significant differences between the three subject groups in either the proportion of apoptotic neutrophils in sputum or the *in vitro* anti-apoptotic activity detected in the sputum fluid phase. Prolonged survival of neutrophils in sputum is not a feature of COPD and cannot explain the increased numbers of airway neutrophils in this disease.

Word count: 199

Introduction

Neutrophil accumulation in the airways is recognised as a prominent feature of chronic obstructive lung disease (COPD), with the extent of neutrophilic infiltration in both the airway lumen and tissues correlating with the disease severity [1-4]. It has been widely hypothesised that neutrophils become activated in the airways to release reactive oxygen species, proteases, and inflammatory cytokines which play an important role in lung injury [5,6]. However, little is known about the cellular and molecular mechanisms that control neutrophil migration and survival in the airways in COPD.

Neutrophil accumulation is a dynamic process that consists of their recruitment from the bloodstream and clearance from the lungs as a result of phagocytosis of apoptotic cells. Neutrophils are attracted from the vascular space into the airway lumen by chemotactic factors, such as interleukin 8 (IL-8), leukotriene B₄ (LTB₄), and tumour necrosis factor alpha (TNF- α). Previous studies have suggested that circulating neutrophils isolated from subjects with COPD are more responsive to chemotactic stimuli than neutrophils from healthy control subjects [7]. However, it is not known whether prolonged cell survival due to reduced apoptosis of neutrophils in the airways also contributes to the accumulation of these cells. Apoptosis is a morphologically and biochemically distinct form of cell death that limits tissue injury and is an essential requirement for the resolution of inflammation [8]. Neutrophil apoptosis has been studied extensively and shown to involve typical morphological changes, attenuation of activation and degranulation, nuclear and cytoplasmic condensation, DNA fragmentation, dilatation of the endoplasmic reticulum and alterations in cell membrane

composition. Further characteristic features are activation of caspases and leakage of cytochrome *c* from the mitochondria [9,10]. Apoptotic neutrophils are removed by macrophages using phagocyte recognition mechanisms [8]. Dysregulation of neutrophil apoptosis leads to their accumulation within the tissue, persistence of inflammation and increased potential for tissue damage. A variety of pro-inflammatory cytokines and other mediators have been demonstrated to delay neutrophil apoptosis *in vitro*; these include granulocyte macrophage colony stimulating factor (GM-CSF), IL-8, and LTB₄, all of which have been shown to be increased in the airways of subjects with COPD (review Barnes PJ et al. [11]).

Little is known about the role of neutrophil apoptosis in COPD. Two studies that have examined spontaneous apoptosis of peripheral blood neutrophils [12,13] have not found any difference in the rate of *in vitro* apoptosis of circulating neutrophils from subjects with stable COPD when compared to healthy smokers or healthy control subjects. We have hypothesised that the presence of higher concentrations of pro-neutrophil factors in the airways prolong neutrophil survival, resulting in fewer apoptotic neutrophils being seen in the sputum of subjects with COPD. To test this hypothesis, we have used induced sputum, a medium that samples the airway lining fluid and is rich in neutrophils and mediators that have a potential to delay neutrophil apoptosis [1]. Further evidence of altered survival of neutrophils in COPD airways was sought by studying the *ex vivo* anti-apoptotic effects of the sputum fluid phase on blood neutrophils.

Methods

Subjects

Twenty subjects with COPD, 14 healthy smokers and 14 healthy control subjects were recruited (Table 1). COPD was diagnosed according to GOLD guidelines [14]. All the COPD subjects and healthy smokers were current smokers with mean 39 and 30 pack-years, respectively. Healthy smokers were free of chronic respiratory symptoms and had normal spirometry. Healthy control subjects were non-smokers without significant past or current respiratory symptoms and with normal lung function. None of the subjects had had any signs of a respiratory infection in the four weeks preceding the study and none were treated with inhaled or oral steroids. None of the subjects had any other chronic disease.

The COPD subjects were classified into GOLD stage 0 to 4 severity categories on the basis of their post-bronchodilator FEV_1/FVC and FEV_1 (% predicted), resulting in eight subjects in stage 0, three subjects in stage I, eight subjects in stage II, and one subject in stage IV (Table 1). COPD stage 0 subjects were current smokers with chronic cough and sputum production but normal lung function ($FEV_1 > 80\%$ of predicted and $FEV_1/FVC > 0.7$). The other COPD subjects were classified into GOLD stage 1 to 4 severity categories on the basis of their post-bronchodilator FEV_1/FVC ($FEV_1/FVC < 0.7$) and FEV_1 (stage 1: $FEV_1 > 80\%$, stage 2: $50\% < FEV_1 < 80\%$, stage 3: $30\% < FEV_1 < 50\%$, stage 4: $FEV_1 < 30\%$). Transfer factor was measured by standard methods [15].

Sputum samples for both the cytological analyses and the *in vitro* experiments with cultured neutrophils were obtained from all the subjects. For the *in vitro* experiments, neutrophils were isolated from 4 separate individuals with no smoking history or lung disease.

The study was approved by the Ethics Committees of the Southampton University Hospital Trust and Helsinki University Hospital. All subjects gave full informed consent.

Sputum induction and processing

Sputum induction was conducted using the guidelines of the European Respiratory Society's Task Force [16]. A standard procedure of induction was conducted using 4.5% hypertonic saline given at 5-min intervals for a maximum of 20 min, with mean induction times being similar in the three subject groups. The mucoid components of sputum were selected in order to reduce salivary contamination and processed as described [17] with slight modifications. Briefly, expectorated samples were divided into two parts: one part was treated by adding four volumes of phosphate-buffered saline (PBS) solution and another was processed with four volumes of dithioerythritol (DTE). Both suspensions were filtered through 70- μ m nylon gauze and centrifuged at 400 g at 4°C for 10 min. The DTE-processed samples were used to make cytopins for total and differential cell counts. The fluid phase of PBS-processed samples was aliquoted and used for the *in vitro* apoptosis assays. The total protein contents of sputum supernatants (μ g/ml) were measured using the Bradford protein assay (Biorad, Hercules, CA, US) in order to adjust the *in vitro* results. For cell differential counts, 400 non-squamous cells were counted on cytopins stained by the Diff-Quick method [18].

Assessment of apoptotic neutrophils

Neutrophil apoptosis was assessed by morphological criteria and flow cytometry (only for *in vitro* assays). The morphological criteria were the disappearance of chromatin bridges between nuclear lobes (early apoptosis), and shrinkage or fragmentation of the nucleus (late apoptosis) (Figure 1). The percentage of apoptotic neutrophils was assessed by counting 400

neutrophils. This was done by two independent observers with good inter-observer reproducibility (intraclass correlation coefficient 0.80). The results were, therefore, expressed as the mean of two counts obtained by the two observers.

Apoptosis was also assessed by flow cytometry using the technique of Vermes and co-workers [19], in which binding of Annexin V (AxV) detects phosphatidylserine externalised on the outer leaflet of the cell membrane of apoptotic cells. Briefly, neutrophils were washed twice in cold PBS and were then re-suspended at a density of 1×10^6 cells/100 μ l of binding buffer (10 mM HEPES pH 7.4, 140 mM NaCl, 2.5 mM CaCl_2) in 5 ml propylene FACS tubes. AxV-PE (1 μ g/ml) and 7-aminoactinomycin D (7AAD) (2.5 μ g/ml) were added to the tubes and incubated in the dark for 15 min, after which 300 μ l of cold binding buffer were added and cells analysed using a FACScan flow cytometer (Becton and Dickinson, Oxford, UK). Control tubes lacking AxV-PE, 7-AAD, or both were included. Analysis of dotplots of fl2 (AxV-PE) versus fl3 (7-AAD) was performed using WinMDI 2.8™. The degree of early apoptosis was shown as the number of $\text{AxV}^+/\text{7AAD}^-$ cells expressed as a percentage of total cells. $\text{AxV}^-/\text{7AAD}^-$ were counted as viable cells, whereas late apoptotic and necrotic cells were counted as $\text{AxV}^+/\text{7AAD}^+$ and $\text{AxV}^-/\text{7AAD}^+$.

Anti-apoptotic effects of induced sputum fluid phase on cultured blood neutrophils

The ability of sputum constituents to modulate neutrophil survival *in vitro* was investigated by culturing peripheral blood neutrophils purified from heparinised blood for 22 hr (the time-point being identified in pilot experiments as being optimal) in the presence or absence of PBS-processed sputum fluid phase. We chose 22 hrs for all the experiments because the

signal is consistent at this time-point, with a median reduction in survival of 68% when neutrophils cells are incubated with sputum supernatants.

GM-CSF was used as a positive control because of its known ability to reduce apoptosis *in vitro* [8]. PBS was used as a negative control. All the sputum fluid phase samples were pre-treated by irradiation with a dosage of 100 Grays (Gy) to prevent bacterial growth which could affect the survival of neutrophils in culture. Heparinised venous blood was obtained from 4 healthy volunteers and neutrophils were isolated by dextran sedimentation/Lymphoprep (Axis-shield, Oslo, Norway) centrifugation at $800\times g$ for 25 min at 20°C . Removal of contaminating erythrocytes was achieved by hypotonic lysis. The remaining granulocytes were washed with culture medium at $400 g$ for 10 min at 4°C . The purity of the neutrophil population was routinely $>96\%$. Cells were resuspended at 4×10^6 cells/ml in RPMI 1640 supplemented with 20% (v/v) fetal calf serum (FCS, TCS Biologicals, Buckingham, UK), 4 mM L-glutamine, 2 mM sodium pyruvate, 100 U/ml penicillin and 100 $\mu\text{g/ml}$ streptomycin (all from Invitrogen, Paisley, UK). Neutrophils were then incubated in Falcon tubes (Becton and Dickinson) at 37°C in 5% CO_2 atmosphere (final cell volume 0.5 ml, 4×10^6 cells). The experiments with cultured neutrophils were carried out in the presence or absence of sputum supernatants of healthy controls, healthy smokers and patients with COPD, GM-CSF (10ng/ml, R&D Systems, Oxford, UK), and PBS as control. In preliminary studies, serial dilutions (1:10, 1:20 and 1:40) of sputum supernatants were tested for their effect on neutrophil survival in order to find the concentration which gives the maximum effect. The percentage of apoptotic cells in medium alone (in the absence of sputum supernatant) was 38.5% and reduced to between 28% and 30% when using the 1:10 dilution,

between 21% and 30% when using 1:20 dilution and between 33% and 35% when using the 1:40 dilution. The maximum reduction was, therefore, seen at the 1:20 dilution of sputum, and such effects were comparable to the anti-apoptotic actions of 10 ng/ml LPS (which reduced spontaneous apoptosis of neutrophils to 20.6%). This optimal dilution was, therefore, used in all subsequent experiments.

After 22 hr of culture, cells were harvested by centrifugation at 300 g for 10 min at 4°C, washed twice and re-suspended in PBS containing 10% (v/v) heat-inactivated FCS. Apoptotic neutrophils were detected by morphology from cytopins and by flow cytometry as described above. The results were expressed as a percentage of the apoptosis observed in the PBS-treated samples to account for variability between experiments.

Statistics

All the statistical analyses were performed using the SPSS 10.0 software program (SPSS Inc., Chicago, IL, US). As the data were not normally distributed, non-parametric tests were used. Data for individual variables from the several groups were first analyzed by the Kruskal-Wallis test, followed by the Mann-Whitney *U*-test. Correlations between variables were sought using the Spearman rank correlation test. A p-value of <0.05 was considered significant.

Results

Sputum cell differential counts and sputum neutrophil apoptosis

Adequate sputum samples were obtained from all the subjects. The median percentages of squamous cell contamination were 2.5%, 3.6%, and 6.2% for COPD, healthy smokers and

healthy controls, respectively ($p>0.5$). Viability, as assessed by trypan blue was 84%, 91%, and 92%, for COPD, healthy smokers and healthy controls, respectively ($p>0.5$). Subjects with COPD and healthy smokers had a significantly higher percentage of sputum neutrophils than healthy control subjects ($p<0.0001$, $p=0.01$, respectively) (Table 2, Figure 2). COPD subjects also had a significantly lower percentage of sputum macrophages than healthy control subjects ($p<0.0001$). When compared to healthy smokers, subjects with COPD had a lower percentage of sputum macrophages ($p=0.05$) and a tendency towards a higher percentage of sputum neutrophils ($p=0.06$). However, there were no differences between the percentages of apoptotic neutrophils on sputum slides in the different subject groups (Figure 3). A sub-analysis was performed comparing subjects with established COPD with subjects with stage 0 COPD. No significant differences between these sub-groups were seen for any of the parameters of neutrophil apoptosis measured.

There was a significant negative correlation between pack years and FEV_1 % predicted ($r_s=-0.47$, $p=0.005$). The relative neutrophils counts correlated inversely with FEV_1 % predicted ($r_s=-0.43$, $p=0.005$) and DLCO/VA ($r_s=-0.45$, $p=0.05$).

Anti-apoptotic effects of induced sputum extract on cultured blood neutrophils

All the sputum samples contained significant pro-survival activity for neutrophils, as demonstrated by the significant reduction in the numbers of apoptotic cells seen after 22 hr of culture in the presence of the fluid phase of induced sputum when compared to spontaneous apoptosis in culture medium and PBS alone. However, there were no significant differences between the effects of the sputum fluid phase from non-smoking controls, smokers and COPD patients on the extent of neutrophil apoptosis whether assessed by low cytometry or

morphology (Figure 4). There was a good correlation between the two methods to detect apoptosis (flow cytometry vs morphology) ($r_s=0.70$, $p<0.0001$), and Bland-Altman analysis showed good agreement between the two methods (Figure 5). The positive control, GM-CSF, effectively reduced apoptosis as shown in Figure 4.

The mean total protein content of sputum was not significantly different between the three groups (COPD: 259 $\mu\text{g/ml}$, healthy smokers: 253 $\mu\text{g/ml}$, and healthy control subjects: 181 $\mu\text{g/ml}$) and when the apoptosis data were corrected for concentrations of total protein, there were still no significant differences in anti-apoptotic activity of sputum between the subject groups.

Discussion

This study suggests that airways neutrophilia in COPD is not a result of increased pro-survival activity in the airways, i.e. reduced pro-apoptotic mechanisms, involving soluble inflammatory mediators present in the epithelial lining fluid. While this study shows that the sputum fluid phase, which samples the bronchial lining fluid of the larger airways, invariably contains significant activity which extends the survival of neutrophils *ex vivo*, this activity is no different in smokers who are healthy or have COPD and is similar to that in healthy non-smoking subjects.

A number of studies to date have sought to elucidate the mechanisms which promote the accumulation of granulocytes in inflammatory airways diseases. Studies in asthma have shown that sputum contains fewer apoptotic eosinophils, the numbers of which correlate negatively with disease severity [20]. Further studies using the sputum fluid phase and either

guinea pig [21] or human [22] eosinophils have attributed this effect to cytokines GM-CSF and IL-5 [21] and prostaglandin E₂ (PGE₂) [22]. Following the same rationale, we have hypothesized that a similar mechanism could explain the airways neutrophilia that is typical of COPD. However, we found no significant differences in the percentages of apoptotic neutrophils in the sputum of subjects with COPD, healthy smokers and healthy control subjects. Furthermore, the rates of *in vitro* apoptosis of circulating neutrophils incubated with sputum supernatants obtained from all three groups of the individuals were similar. Taken together, this strongly suggests that anti-apoptotic mechanisms, although operative within the airways, are not the basis of airways neutrophilia in COPD. Measuring factors such as IL-8 and GM-CSF was part of our original plan, but we found little justification to explore further which chemokines/cytokines are responsible for cell survival since no differences in cell survival were found.

Eight COPD subjects with stage 0 COPD i.e. chronic respiratory symptoms but normal lung function and 12 subjects with more severe COPD (8 of whom had stage II COPD) were studied. There were no significant differences in the numbers of apoptotic neutrophils or the extent of *in vitro* apoptosis between stage 0 COPD and more severe patients. Moreover, the numbers of apoptotic neutrophils did not correlate with lung function parameters. Thus, it seems that the anti-apoptotic activity in the airways is not a function of COPD severity, although we cannot rule this out for the more severe stages III and IV COPD since only 1 subject with stage IV was included in the analysis.

Apoptosis is an essential mechanism for clearing neutrophils. During apoptosis neutrophils retain their granule contents, lose the ability to secrete them in response to

secretagogues, and lose their phagocytic capacity [8]. Together with the removal of apoptotic neutrophils by macrophages, this limits tissue injury during the resolution phase of inflammation. Inefficient clearance of apoptotic cells because of either less effective or absent macrophages results in secondary necrosis and release of neutrophil activation products that are potentially toxic to the lung [8]. While we have found that sputum macrophage counts, expressed as percentage of total inflammatory cell counts, were lower in patients with COPD than in healthy control subjects this did not seem to affect clearance since the numbers of apoptotic neutrophils were no different in COPD. Phagocytosis of dying neutrophils by macrophages before they undergo secondary necrosis and release toxic metabolites limits tissue injury, inhibits release of pro-inflammatory cytokines and results in the production of anti-inflammatory mediators [23]. It has been shown, that neutrophil elastase can cleave the phosphatidylserine receptor and impair phagocytic recognition mechanisms [24]. It remains, therefore, to be elucidated whether in COPD more neutrophils undergo secondary necrosis as opposed to apoptosis, resulting in higher concentration of neutrophil-derived mediators such as myeloperoxidase and neutrophil elastase (22,23).

Previous studies have shown that *in vitro* neutrophil apoptosis of blood neutrophils from subjects with COPD occurs at a similar rate as in healthy individuals and smokers with normal lung function [12] but is reduced during acute exacerbations of COPD and returns to levels seen in healthy control subjects within two weeks [13]. These observations are in keeping with studies showing reduced apoptosis of blood and BAL neutrophils in acute lung inflammation such as in respiratory distress syndrome (ARDS), pneumonia [25,26] and

exacerbations of bronchiectasis [27]. Therefore, future studies are needed to investigate the effects of COPD exacerbations on airway neutrophil survival.

The question of why sputum neutrophil counts are increased in COPD remains unanswered. We have recently shown a significant correlation between raised neutrophil counts and reduced FEV₁ across the spectrum of COPD severity [4], with both the airflow limitation and sputum neutrophilia being related to the degree of small airways dysfunction, as assessed by expiratory HRCT lung density measurements. A recent study by Hogg and colleagues [3] showed prominent inflammation in the small airways in COPD which correlated with the decline in lung function. It is, therefore, plausible that the sputum neutrophilia which is consistently reported reflects increased accumulation of neutrophils in the small airways and their transport by the mucociliary escalator into the larger airways that are sampled by sputum induction.

In conclusion, neutrophil survival is not significantly altered in the airways of subjects with stable COPD even though their sputum contains increased numbers of neutrophils. It remains to be seen whether neutrophil influx into the airways, directed by increased chemotactic activity, is responsible for this phenomenon and to what extent COPD exacerbations might affect neutrophil survival.

Reference List

1. Keatings VM, Collins PD, Scott DM, Barnes PJ. Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. *Am.J Respir.Crit Care Med.* 1996;153:530-534.

2. Peleman RA, Ryttila PH, Kips JC, Joos GF, Pauwels RA. The cellular composition of induced sputum in chronic obstructive pulmonary disease. *Eur.Respir.J* 1999;13:839-843.
3. Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, Cherniack RM, Rogers RM, Sciurba FC, Coxson HO, Pare PD. The nature of small-airway obstruction in chronic obstructive pulmonary disease. *N.Engl.J Med.* 2004;350:2645-2653.
4. O'Donnell RA, Peebles C, Ward JA, Daraker A, Angco G, Broberg P, Pierrou S, Lund J, Holgate ST, Davies DE, Delany DJ, Wilson SJ, Djukanovic R. Relationship between peripheral airway dysfunction, airway obstruction, and neutrophilic inflammation in COPD. *Thorax* 2004;59:837-842.
5. Rahman I. Oxidative stress, chromatin remodeling and gene transcription in inflammation and chronic lung diseases. *J Biochem.Mol.Biol.* 2003;36:95-109.
6. Repine JE, Bast A, Lankhorst I. Oxidative stress in chronic obstructive pulmonary disease. Oxidative Stress Study Group. *Am.J Respir.Crit Care Med.* 1997;156:341-357.
7. Burnett D, Chamba A, Hill SL, Stockley RA. Neutrophils from subjects with chronic obstructive lung disease show enhanced chemotaxis and extracellular proteolysis. *Lancet* 1987;2:1043-1046.
8. Haslett C. Granulocyte apoptosis and its role in the resolution and control of lung inflammation. *Am.J Respir.Crit Care Med.* 1999;160:S5-11.

9. Granville DJ, Carthy CM, Hunt DW, McManus BM. Apoptosis: molecular aspects of cell death and disease. *Lab Invest* 1998;78:893-913.
10. Green DR. Introduction: apoptosis in the development and function of the immune system. *Semin.Immunol.* 2003;15:121-123.
11. Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. *Eur.Respir.J* 2003;22:672-688.
12. Noguera A, Sala E, Pons AR, Iglesias J, MacNee W, Agusti AG. Expression of adhesion molecules during apoptosis of circulating neutrophils in COPD. *Chest* 2004;125:1837-1842.
13. Pletz MW, Ioanas M, de Roux A, Burkhardt O, Lode H. Reduced spontaneous apoptosis in peripheral blood neutrophils during exacerbation of COPD. *Eur.Respir.J* 2004;23:532-537.
14. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. *Am.J Respir.Crit Care Med.* 2001;163:1256-1276.
15. Single breath carbon monoxide diffusing capacity (transfer factor). Recommendations for a standard technique. Statement of the American Thoracic Society. *Am.Rev.Respir.Dis.* 1987;136:1299-1307.

16. Djukanovic R, Sterk PJ, Fahy JV, Hargreave FE. Standardised methodology of sputum induction and processing. *Eur.Respir.J Suppl* 2002;37:1s-2s.
17. Hadjicharalambous C, Dent G, May RD, Handy RL, Anderson IK, Davies DE, Djukanovic R. Measurement of eotaxin (CCL11) in induced sputum supernatants: validation and detection in asthma. *J Allergy Clin.Immunol.* 2004;113:657-662.
18. Efthimiadis A, Spanevello A, Hamid Q, Kelly MM, Linden M, Louis R, Pizzichini MM, Pizzichini E, Ronchi C, Van Overvel F, Djukanovic R. Methods of sputum processing for cell counts, immunocytochemistry and in situ hybridisation. *Eur.Respir.J Suppl* 2002;37:19s-23s.
19. Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. *J Immunol.Methods* 1995;184:39-51.
20. Duncan CJ, Lawrie A, Blaylock MG, Douglas JG, Walsh GM. Reduced eosinophil apoptosis in induced sputum correlates with asthma severity. *Eur.Respir.J* 2003;22:484-490.
21. Adachi T, Motojima S, Hirata A, Fukuda T, Makino S. Eosinophil viability-enhancing activity in sputum from patients with bronchial asthma, Contributions of interleukin-5 and granulocyte/macrophage colony-stimulating factor. *Am.J Respir.Crit Care Med.* 1995;151:618-623.

22. Profita M, Sala A, Bonanno A, Riccobono L, Siena L, Melis MR, Di Giorgi R, Mirabella F, Gjomarkaj M, Bonsignore G, Vignola AM. Increased prostaglandin E2 concentrations and cyclooxygenase-2 expression in asthmatic subjects with sputum eosinophilia. *J Allergy Clin.Immunol.* 2003;112:709-716.
23. Fadok VA, Bratton DL, Guthrie L, Henson PM. Differential effects of apoptotic versus lysed cells on macrophage production of cytokines: role of proteases. *J Immunol.* 2001;166:6847-6854.
24. Vandivier RW, Fadok VA, Hoffmann PR, Bratton DL, Penvari C, Brown KK, Brain JD, Accurso FJ, Henson PM. Elastase-mediated phosphatidylserine receptor cleavage impairs apoptotic cell clearance in cystic fibrosis and bronchiectasis. *J Clin.Invest* 2002;109:661-670.
25. Droemann D, Aries SP, Hansen F, Moellers M, Braun J, Katus HA, Dalhoff K. Decreased apoptosis and increased activation of alveolar neutrophils in bacterial pneumonia. *Chest* 2000;117:1679-1684.
26. Matute-Bello G, Liles WC, Radella F, Steinberg KP, Ruzinski JT, Jonas M, Chi EY, Hudson LD, Martin TR. Neutrophil apoptosis in the acute respiratory distress syndrome. *Am.J Respir.Crit Care Med.* 1997;156:1969-1977.
27. Watt AP, Brown V, Courtney J, Kelly M, Garske L, Elborn JS, Ennis M. Neutrophil apoptosis, proinflammatory mediators and cell counts in bronchiectasis. *Thorax* 2004;59:231-236.

Figure legends

Figure 1. Sputum neutrophils (figure 1a). Normal neutrophils have at least two nuclear lobes interconnected by thin chromatin bridges (black arrows). Cells undergoing early apoptosis lose the chromatin bridges (blue arrow).

Figure 1a.



Figure 1b. Neutrophils after 22 h culture. Two normal neutrophils can be seen (black arrows). In cells undergoing late apoptosis, there is considerable shrinkage of the cell nucleus due to condensation of nuclear chromatin (red arrows). Occasionally, in late apoptotic neutrophils there is also fragmentation of the nucleus resulting in distinct apoptotic bodies (shown by the green arrows).

Figure 1b.




Figure 2. Sputum neutrophil counts (shown as percentages of non-squamous cells).

Horizontal lines represent median values.




Figure 3. Sputum apoptotic neutrophil counts (shown as percentages of non-squamous cells).

Horizontal lines represent median values





Figure 4. Neutrophil apoptosis after 22 hr culture of blood-derived neutrophils with sputum supernatants from the three subject groups (4a early apoptosis by flow cytometry, 4b total apoptosis by flow cytometry and 4c apoptosis by morphology). GM-CSF was used as a positive control and PBS as a negative control. Data are shown as percentages of apoptotic neutrophils seen in control culture medium and PBS alone. Horizontal lines represent median values






Figure 5. Bland-Altman plot for neutrophil apoptosis as assessed by FACS and morphology.

Upper and lower limits of agreement are shown with dashed lines.

Figure 5.




Table 1. Patient characteristics.

| | COPD n=20 | Healthy smokers n=14 | Healthy controls n=14 |
|---|----------------------------|---------------------------------------|--|
| Sex, male/female | 9/11 | 9/5 | 9/5 |
| Age, yrs | 55 (41-72) | 50 (22-64) | 44 (20-62) |
| Smoking, pack-years | 39 (17-75) | 30 (5-60) | - |
| Post-bronchodilator FEV ₁ (% pred)* | 78 (25-109) | 93 (72-110) | 105 (86-128) |
| Post-bronchodilator FEV ₁ /FVC (%)† | 66 (28-87) | 78 (71-88) | 79 (70-94) |
| DLCO/VA (% pred) † | 53 (28-82) | 75 (50-96) | Not done |

Data shown as mean (range) for lung function and median (range) for age and smoking,

* p<0.0001, †p<0.01.

Table 2. Induced sputum cell counts and apoptosis data from sputum cytopins.

| | COPD n=20 | Healthy Smokers n=14 | Healthy Controls n=14 | p-value |
|--|----------------------|-------------------------------------|--------------------------------------|----------------|
| Total cell count (x10 ³ /mg of sputum) | 2.8 (0.9-17) | 2.2 (0.4-4.4) | 1.8 (0.3-19) | ns |
| Viability (%) | 84 (60-100) | 91 (50-100) | 92 (88-95) | ns |
| Abs neutrophils (x10 ⁶ /g) | 0.54 (0.16-5.90) | 0.51 (0.03-2.90) | 0.41 (0.25-6.29) | ns |
| Neutrophils (%) | 58 (36-89) | 54 (28-79) | 30 (0-61) | <0.0001 |
| Abs macrophages (x10 ⁶ /g) | 0.46 (0.08-1.27) | 0.50 (0.07-2.26) | 0.82 (0.23-5.6) | ns |
| Macrophages (%) | 37 (8.3-63) | 43 (20-71) | 63 (37-95) | 0.001 |
| Eosinophils (%) | 0.2 (0-3.0) | 0 (0-2.0) | 0 (0-1.0) | ns |
| Lymphocytes (%) | 0.5 (0-2.0) | 0 (0-2.0) | 0.4 (0-2.8) | ns |
| Abs apoptotic neutrophils (x10 ⁶ /g) | 0.41 (0.04-1.8) | 0.44 (0.02-1.11) | 0.31 (0.05-3.93) | ns |
| Apoptotic neutrophils (%) | 36 (16-71) | 36 (22-66) | 34 (18-55) | ns |

Data are shown as median and range. The cell counts are shown as absolute counts expressed per weight (grams) of sputum and percentages of total inflammatory cells, excluding squamous cells, ns=not significant.